Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma

Eric Salazar, Katherine K. Perez, Madiha Ashraf, Jian Chen, Brian Castillo, Paul A. Christensen, Taryn Eubank, David W. Bernard, Todd N. Eagar, S. Wesley Long, Sishir Subedi, Randall J. Olsen, Christopher Leveque, Mary R. Schwartz, Monisha Dey, Cheryl Chavez-East, John Rogers, Ahmed Shehabeldin, David Joseph, Guy WilliamsKaren Thomas, Faisal Masud, Christina Talley, Katharine G. Dlouhy, Bevin V. Lopez, Curt Hampton, Jason Lavinder, Jimmy D. Gollihar, Andre C. Maranhao, Gregory C. Ippolito, Matthew O. Saavedra, Concepcion C. Cantu, Prasanti Yerramilli, Layne Pruitt, James M. Musser

Producción científica: Articlerevisión exhaustiva

194 Citas (Scopus)


Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and no proven treatments are available. Convalescent plasma therapy has been used with varying degrees of success to treat severe microbial infections for >100 years. Patients (n = 25) with severe and/or life-threatening COVID-19 disease were enrolled at the Houston Methodist hospitals from March 28, 2020, to April 14, 2020. Patients were transfused with convalescent plasma, obtained from donors with confirmed severe acute respiratory syndrome coronavirus 2 infection who had recovered. The primary study outcome was safety, and the secondary outcome was clinical status at day 14 after transfusion. Clinical improvement was assessed on the basis of a modified World Health Organization six-point ordinal scale and laboratory parameters. Viral genome sequencing was performed on donor and recipient strains. At day 7 after transfusion with convalescent plasma, nine patients had at least a one-point improvement in clinical scale, and seven of those were discharged. By day 14 after transfusion, 19 (76%) patients had at least a one-point improvement in clinical status, and 11 were discharged. No adverse events as a result of plasma transfusion were observed. Whole genome sequencing data did not identify a strain genotype-disease severity correlation. The data indicate that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.

Idioma originalEnglish (US)
Páginas (desde-hasta)1680-1690
Número de páginas11
PublicaciónAmerican Journal of Pathology
EstadoPublished - ago 2020
Publicado de forma externa

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Profundice en los temas de investigación de 'Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma'. En conjunto forman una huella única.

Citar esto